Could a blood thinner stop liver crisis? new trial launches in pakistan
NCT ID NCT07521332
First seen Apr 17, 2026 · Last updated Jun 16, 2026 · Updated 13 times
Summary
This study tests whether adding a blood thinner (apixaban) to a standard heart drug (carvedilol) can prevent serious complications like bleeding, fluid buildup, and confusion in people with liver scarring (cirrhosis). About 220 adults with cirrhosis and high blood pressure in the liver will be randomly assigned to get either the combination or a placebo plus carvedilol. The goal is to see if the combination reduces hospitalizations and deaths over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asian Institute of Medical Sciences
RECRUITINGHyderābād, Sindh, 71000, Pakistan
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.